Business
ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives
Biopharma leaders bring proven market development talents in urology and oncology to bolster company’s commercialization plan and long-term growth plans
About this update from Immunitybio, Inc.
[{"type":"text","content":"\nBiopharma leaders bring proven market development talents in urology and oncology to bolster company’s commercialization plan and long-term growth plans\n\n\nHelen Luu, former CEO of Cell BT, is named ImmunityBio’s first Chief Commercial Officer and brings a strong background in product commercialization in the urology market, business development, sales growth, and oncology market expansion.\n\n\nSigrid Schreiner joins as Senior Vice President of Global Market Access, adding decades of market access experience to the leadership team, including the market launch of chemotherapy Abraxane®.\n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced two key executive appointments that bring industry-leading market growth and access experience to the company. Helen Luu will serve as the company’s first Chief Commercial Officer, joining ImmunityBio from her position as CEO of CAR-T developer Cell BT. The company also named Sigrid Schreiner as Senior Vice President of Global Market Access. She joins the company from Stemline Therapeutics (now Menarini Group), a global commercial-stage oncology therapeutics company.\n\n“The timing is right for ImmunityBio to build out our commercial team and we could not have chosen stronger commercial leaders than Helen and Sigrid,” said Richard Adcock, President and CEO, ImmunityBio. “Their combined 35 years of commercial expertise in oncology therapeutics is well aligned with our growth strategy as we advance our Phase 3 trials for bladder and lung cancer and continue to make progress with our various Phase 2 trials. We are excited to have them on our team and value the energy they will inject into this key aspect of the business.”\n\nAs Chief Commercial Officer, Luu will take on the vital responsibilities of the company’s global commercial strategy, including the design and execution of expansion into the oncology and urology markets, as well as establishing key external alliances to support the commercial success of ImmunityBio. With more than 16 years of experience in multichannel and specialty biotech operations, Luu thrives in rapidly changing, highly competitive environments and specializes in business development, corporate restructuring, sales optimization, and process improvement to drive corporate revenue.\n\n“I...